Title |
Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin
|
---|---|
Published in |
BMC Infectious Diseases, February 2015
|
DOI | 10.1186/s12879-015-0781-7 |
Pubmed ID | |
Authors |
Alexander Guschin, Pavel Ryzhikh, Tatiana Rumyantseva, Mikhail Gomberg, Magnus Unemo |
Abstract |
Azithromycin has been widely used for Mycoplasma genitalium treatment internationally. However, the eradication efficacy has substantially declined recent decade. In Russia, josamycin (another macrolide) is the recommended first-line treatment for M. genitalium infections, however, no data regarding treatment efficacy with josamycin and resistance in M. genitalium infections have been internationally published. We examined the M. genitalium prevalence in males attending an STI clinic in Moscow, Russia from December 2006 to January 2008, investigated treatment efficacy with josamycin in male urethritis, and monitored the M. genitalium DNA eradication dynamics and selection of macrolide resistance in M. genitalium during this treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 110 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 15 | 14% |
Researcher | 13 | 12% |
Student > Ph. D. Student | 13 | 12% |
Student > Bachelor | 13 | 12% |
Student > Doctoral Student | 7 | 6% |
Other | 17 | 15% |
Unknown | 32 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 16 | 15% |
Medicine and Dentistry | 15 | 14% |
Biochemistry, Genetics and Molecular Biology | 9 | 8% |
Immunology and Microbiology | 9 | 8% |
Nursing and Health Professions | 5 | 5% |
Other | 23 | 21% |
Unknown | 33 | 30% |